Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care

Collaborative Care of Opioid-Addicted Patients in Primary Care Using Buprenorphine

(2011) Daniel P. Alford et al.   ARCHIVES OF INTERNAL MEDICINE

The Evidence Doesn’t Justify Steps By State Medicaid Programs To Restrict Opioid Addiction Treatment With Buprenorphine

(2011) Robin E. Clark et al.   HEALTH AFFAIRS

Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial

(2010) Daniel Polsky et al.   ADDICTION

Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes

(2010) Jeffrey M. Pyne et al.   ADDICTION

The quality of eight health status measures were compared for chronic opioid dependence

(2010) Bohdan Nosyk et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy

(2009) T.V. Parran et al.   DRUG AND ALCOHOL DEPENDENCE

What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?

(2009) R Scott Braithwaite et al.   MEDICAL CARE

Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients

(2008) Emlyn S. Jones et al.   DRUG AND ALCOHOL DEPENDENCE

Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth

(2008) George E. Woody et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

(2008) Scott D Grosse   Expert Review of Pharmacoeconomics & Outcomes Research